FDA
-
-
-
-
-
-
-
DEADLINE ALERT for TCPC, ORCL, PSFE, and INO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
-
-
-
-
-
-
-
Holzer & Holzer, LLC Reminds INO Investors of the April 7, 2026 Lead Plaintiff Deadline in the Inovio Pharmaceuticals, Inc. Securities Class Action
-
-
-
-
-
-
-
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
-
-
-
-
-
-
-
Jefferies on Inovio Pharmaceuticals (INO): 'Our near-term focus is on Type B outcome expected in ~50 days + ~30 days meeting minutes'
-
-
-
-
-
-
-
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
-
-
-
-
-
-
-
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

